Circular Genomics and Altoida announced a collaboration to combine Circular Genomics’ blood-based circular RNA biomarker platform with Altoida’s AI-powered Digital NeuroMarker platform to develop a multimodal approach for Alzheimer’s drug
Alzinova AB, a Swedish clinical-stage biopharmaceutical, is advancing a dual approach to alzheimer’s disease by initiating the global phase II start-up of its therapeutic vaccine ALZ-101 and developing a blood-based
NKGen Biotech announced that Chairman and CEO Paul Y. Song, M.D., will present on troculeucel, the company’s lead investigational program, at Biologics Manufacturing Korea 2026 in Incheon on 17-18 Sept.
Alzheon announced a peer-reviewed publication presenting integrated analyses of Phase 3 APOLLOE4 and Phase 2 data that, according to the company, showed early and sustained reductions in plasma p-tau217 and
Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive
Oligomerix has appointed Dr. Cara Cassino as interim president and chief executive officer as the privately held biotech moves from discovery toward clinical development of its lead Alzheimer’s candidate. Cassino
Retro Biosciences is expanding its phase 1 safety trial of RTR 242 by adding two higher-dose cohorts and increasing enrollment from 76 to 108 participants, a more than 42% rise.
Anavex reported a business update and financial results for the third fiscal quarter ended 30 June. The company has submitted all data from its Alzheimer’s disease clinical trials to a
Eisai has begun U.S. availability of lecanemab-irmb subcutaneous injection, branded in the U.S. as Leqembi Iqlik, for initiation therapy in early Alzheimer’s disease after FDA approval on 13 July, according
